1. Smeyers, Julie, Banchi, Elena-Gaia, Latouche, Morwena. 2021. C9ORF72: What It Is, What It Does, and Why It Matters. In Frontiers in cellular neuroscience, 15, 661447. doi:10.3389/fncel.2021.661447. https://pubmed.ncbi.nlm.nih.gov/34025358/
2. Meijboom, Katharina E, Brown, Robert H. 2022. Approaches to Gene Modulation Therapy for ALS. In Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 19, 1159-1179. doi:10.1007/s13311-022-01285-w. https://pubmed.ncbi.nlm.nih.gov/36068427/
3. Fang, Ton, Je, Goun, Pacut, Peter, Gao, Jeff, Ghasemi, Mehdi. 2022. Gene Therapy in Amyotrophic Lateral Sclerosis. In Cells, 11, . doi:10.3390/cells11132066. https://pubmed.ncbi.nlm.nih.gov/35805149/
4. McCauley, Madelyn E, O'Rourke, Jacqueline Gire, Yáñez, Alberto, Jefferies, Caroline, Baloh, Robert H. 2020. C9orf72 in myeloid cells suppresses STING-induced inflammation. In Nature, 585, 96-101. doi:10.1038/s41586-020-2625-x. https://pubmed.ncbi.nlm.nih.gov/32814898/
5. DeJesus-Hernandez, Mariely, Mackenzie, Ian R, Boeve, Bradley F, Graff-Radford, Neill R, Rademakers, Rosa. 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. In Neuron, 72, 245-56. doi:10.1016/j.neuron.2011.09.011. https://pubmed.ncbi.nlm.nih.gov/21944778/